# US 2010/0168216 A1 · Prostaglandin pharmaceutical compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168216 A1
- Document ID: US20100168216A1
- Status: Published application
- Kind: A1
- Application number: 12/601,742
- Filed: 2008-03-06
- Published: 2010-07-01
- Earliest claimed: 2007-05-25
- Assignees: Ctg Pharma S.R.L.
- Inventors: Piero Del Soldato; Giancarlo Santus; Anna Sparatore
- Web page: https://patentgrep.com/patent/US20100168216A1

## CPC

- C07C 405/00: Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins {; Analogues or derivatives thereof}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 15/04: for inducing labour or abortion; Uterotonics
- A61P 15/10: for impotence
- A61P 27/02: Ophthalmic agents
- C07D 339/04: having the hetero atoms in positions 1 and 2, e.g. lipoic acid
- C07C 2601/08: the ring being saturated
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to new prostaglandin derivatives having improved pharmacological activity and enhanced tolerability. They can be employed for the treatment of glaucoma and ocular hypertension.

## Claims

### Claim 1

Compounds of general formula (I):
A—Y—W (I)
wherein
A is a residue of prostaglandins or their derivatives of formula (II):
B is —(CH2)m—CH3, m is 1-5; or
V1 and V2, the same or different to each other, are zero or H;
the bond is a single bond when V1 and/or V2 are H or a double bond;
Y is zero; —(Cn′)alkyl-, ˜(Cn′)alkyl-CO—, ˜O—(Cn′)alkyl-O—, ˜OOC—(Cn′)alkyl-COO—; ˜O—(Cn′)alkyl-, ˜HN—(Cn′)alkyl-, ˜OOC—(Cn′)alkyl-; ˜(Cn′)alkyl-O—CO—(Cn″)alkyl-; ˜(Cn′)alkyl-CO—O—(Cn″)alkyl- wherein (Cn′)alkyl and (Cn″)alkyl are straight or branched, and n′ and n″, the same or different to each other, are 0-10;
W is a polysulfurated group containing 2 or more atoms of sulphur, selected from the group comprising an organic thiosulfonate moiety or a dithiole-thione derivative, their stereoisomers and salts thereof.

### Claim 2 (depends on 1)

Compounds of general formula (I) according to claim 1, wherein W is an organic thiosulfonate moiety having formula:
˜S—SO2—R (III)
wherein ˜S—SO2—R is linked to A-Y˜; R is a straight or branched alkyl, selected from the group comprising methyl, ethyl, propyl; alkenyl, alkinyl; alkylaryl, alkenylaryl, alkinylaryl; arylalkyl, arylalkenyl, arylalkinyl or cycloalkyl, cycloalkenyl, cycloalkinyl, or aromatic and/or heterocyclic ring, all substituted or unsubstituted.

### Claim 3 (depends on 1)

Compounds of general formula (I) according to claim 1, wherein W is a dithiole-thione derivative having formula:
wherein
Z is S (sulphur) and at least 1 Z is a thione C═S; and T is:
˜OOC—; or
wherein
R1 is H; —COOH; —NH2; —OH; —SH;
R2 is hydrogen; —COOH; alkyl, alkenyl, alkynyl; aryl; fluoro, chloro, bromo; hydroxyl, alkyloxy, alkenyloxy, aryloxy, acyloxy; amino, alkylamino, arylamino; thio; cyano; nitro; acyl; amido; and a 5 or 6-membered aromatic or non-aromatic ring containing 0, 1, or 2 heteroatoms selected from nitrogen, oxygen, or sulphur.

### Claim 4 (depends on 1)

Salts of compounds of general formula (I) according to claim 1, wherein said salts are pharmaceutical acceptable salts of compounds of formula (I).

### Claim 5 (depends on 4)

Salts according to claim 4, said salts comprising salts of compounds of formula (I) with: alkaline metals and alkaline earth metals, non-toxic amines and aminoacids, inorganic acids comprising hydrochloric acid, phosphoric acid or organic acids comprising fumaric acid, citric acid, tartaric acid.

### Claim 6 (depends on 2)

Compounds of general formula (I) according to claim 2, wherein the group —Y—W is selected from the group comprising thiosulfonate moieties derived from the corresponding precursors having formula: S-(2-carboxyethyl)methanthiosulfonate, S-(2-aminoethyl)methanthiosulfonate and S-(2-hydroxyethyl)methanthiosulfonate.

### Claim 7 (depends on 3)

Compounds of general formula (I) according to claim 3, wherein the polysulfurated group W is selected from the group comprising dithiole-thione derivatives of the corresponding precursors having formula: 5-(p-hydroxyphenyl)-3H-1,2-dithiol-3-thione, 1,3-dithiol-2-thione-5-carboxylic acid, 3-thioxo-3H-1,2-dithiole-5-carboxylic acid, 3-thioxo-3H-1,2-dithiole-4-carboxylic acid.

### Claim 8 (depends on 1)

Compound of general formula (I) according to claim 1, wherein said compound is (11α,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid 4-(3H-1,2-dithiole-3-thione-5-yl)-phenyl ester.

### Claim 9 (depends on 1)

Compound of general formula (I) according to claim 1, wherein said compound is (5Z)-7-[(IR,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoic acid 4-(3H-1,2-dithiole-3-thione-5-yl)-phenyl ester.

### Claim 10 (depends on 1)

Compound of general formula (I) according to claim 1, wherein said compound is (11α,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid 2-(methylsulfonylthio)ethyl ester.

### Claim 11 (depends on 1)

Compound of general formula (I) according to claim 1, wherein said compound is (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoic acid 2-(methylsulfonylthio)ethyl ester.

### Claim 12 (depends on 1)

Compound of general formula (I) according to claim 1, wherein said compound is (11α,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid 2-(methylsulfonylthio)ethylamide.

### Claim 13 (depends on 1)

Compound of general formula (I) according to claim 1, wherein said compound is (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoic acid 2-(methylsulfonylthio)ethylamide.

### Claim 14 (depends on 1)

Compound of general formula (I) according to claim 1, wherein said compound is (5Z,9α,11α,13E,15S)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprosta-5,13-dienoic acid 2-(methylsulfonylthio)ethylamide.

### Claim 15 (depends on 1)

Pharmaceutical composition comprising at least a compound of general formula (I) according to claim 1 as an active ingredient and eventually one or more pharmaceutically acceptable adjuvant(s) or carrier(s).

### Claim 16 (depends on 1)

Compound of general formula (I) according to claim 1 for use as a medicament.

### Claim 17 (depends on 1)

Use of a compound of general formula (I) according to claim 1 for the manufacture of a medicament for prevention, treatment of ocular diseases.

### Claim 18 (depends on 1)

Use of a compound of general formula (I) according to claim 1 for the manufacture of a medicament for treatment of ocular diseases, in combination with other ophthalmic agents.

### Claim 19 (depends on 1)

Use of a compound of general formula (I) according to claim 1 for the manufacture of a medicament for prevention, treatment and reduction of erectile dysfunction, cerebrovascular and cardiovascular disorders, peptic ulcer disorders and for inducing abortion.

### Claim 20 (depends on 1)

Process for the synthesis of compounds of general formula (I) according to claim 1, comprising at least a reaction between the corresponding precursor of an organic thiosulfonate or dithiol-thione, moiety W or Y—W, and a prostaglandin compound or at least a reaction between the corresponding precursor of an organic thiosulfonate or dithiol-thione, moiety W and a corresponding precursor of a prostaglandin modified with Y, wherein W and Y have the meaning according to claim 1.
